The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
BUSINESS
Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
Takeda Pharmaceutical announced on February 10 that the novel oral proteasome inhibitor ixazomib (development code: MLN9708) achieved its primary endpoint of improving progression-free survival (PFS) in an interim analysis of the PIII TOURMALINE-MM1 study. Takeda expects to file for marketing…
To read the full story
BUSINESS
- Kaken to Snatch Up Aadi Subsidiary for US$100 Million to Establish Global Footprint
December 23, 2024
- Oncolys Grants Telomelysin Commercial Rights to Medigen in Taiwan
December 23, 2024
- AbbVie Files Venclexta for Untreated CLL in Japan
December 23, 2024
- Astellas Snags Rights to Sangamo’s AVV Capsid for Neurological Diseases
December 20, 2024
- Xocova to Be Re-Filed in South Korea with Additional Data
December 20, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…